What IV pre‑medications should be administered before a rituximab infusion?

IV Pre-Medications Prior to Rituximab Infusion

All patients receiving rituximab must be premedicated with acetaminophen (650–1000 mg orally) and an antihistamine (diphenhydramine 25–50 mg orally or IV) administered 30 minutes before each infusion. 1, 2, 3

Standard Premedication Protocol

Core Pre-Medications (Mandatory for All Patients)

• Acetaminophen: 650–1000 mg orally, given 30 minutes before infusion 1, 2, 3
• Antihistamine: Diphenhydramine 25–50 mg orally or IV, given 30 minutes before infusion 1, 2, 3

Corticosteroid Pre-Medication (Indication-Specific)

For rheumatoid arthritis, granulomatosis with polyangiitis (GPA), microscopic polyangiitis (MPA), and pemphigus vulgaris (PV):

• Methylprednisolone 100 mg IV (or equivalent) administered 30 minutes prior to each rituximab infusion 3

For pediatric patients with GPA/MPA:

• Methylprednisolone 30 mg/kg IV (maximum 1 gram) given once daily for 3 days prior to the first rituximab infusion 3

For lymphoma patients receiving rituximab with chemotherapy:

• The glucocorticoid component of the chemotherapy regimen (e.g., prednisone in R-CHOP) should be administered prior to rituximab infusion 3
• For patients with high tumor burden or first infusion, methylprednisolone 100 mg IV is strongly recommended 30 minutes before infusion 1

For patients with history of prior infusion reactions (Grade 2 or higher):

• Methylprednisolone 40 mg IV (or up to 15 mg/kg for severe prior reactions) administered 20–30 minutes before infusion 1, 4

Enhanced Pre-Medication for High-Risk Patients

Patients at increased risk for severe infusion reactions include those with:

• High tumor burden (lymphocyte count >25 × 10⁹/L, bulky masses, elevated LDH) 1, 5
• History of Grade 2–4 infusion reactions 1, 4
• Known cardiovascular disease or risk factors 5

For these high-risk patients, add:

• Corticosteroids: Methylprednisolone 100 mg IV reduces severe reactions from 4.7% to 1% 1
• Consider slower initial infusion rate (50% of standard rate) 1

Prophylactic Antimicrobial Medications

Pneumocystis jirovecii Pneumonia (PCP) Prophylaxis

For chronic lymphocytic leukemia (CLL) patients:

• PCP prophylaxis is mandatory during rituximab treatment and for up to 12 months following the last infusion 3

For GPA/MPA patients:

• PCP prophylaxis is recommended during treatment and for at least 6 months following the last rituximab infusion 3

For pemphigus vulgaris patients:

• PCP prophylaxis should be considered during and following rituximab treatment 3

Herpes Virus Prophylaxis

For CLL patients:

• Herpes virus prophylaxis is recommended during treatment and for up to 12 months following treatment 3

Critical Pre-Infusion Screening and Monitoring

Hepatitis B Screening (Mandatory)

• All patients must be screened for hepatitis B (HBsAg and anti-HBc) before initiating rituximab due to risk of fatal viral reactivation 1, 3
• HBsAg-positive patients require concurrent antiviral therapy if rituximab is deemed essential 6
• Anti-HBc-positive (occult carriers) patients should receive prophylactic antiviral therapy 6

Baseline Laboratory Assessment

• Immunoglobulin levels (IgG, IgM, IgA) should be measured at baseline to identify patients at risk for hypogammaglobulinemia 2
• Complete blood count, hepatic and renal function tests 1

Common Pitfalls to Avoid

• Never omit acetaminophen and antihistamine premedication, even for subsequent infusions, as this increases infusion reaction risk 1, 3
• Do not assume corticosteroid premedication is optional for RA, GPA, MPA, or PV patients—methylprednisolone 100 mg IV is specifically recommended for these indications 3
• Failing to screen for hepatitis B can result in fulminant hepatic failure and death 1
• Do not use first-generation antihistamines (diphenhydramine) for treatment of active infusion reactions, as they may exacerbate hypotension; however, diphenhydramine remains appropriate for pre-medication 6
• Recognize that 77% of infusion reactions occur during the first infusion, with 82–95% of all reactions happening during or immediately after the initial dose 1, 2